Keyphrases
Erenumab
100%
Episodic Migraine
100%
Randomized Phase III Trial
100%
Placebo
62%
Migraine
50%
Monthly Migraine Days
50%
Physical Function
37%
Diary
37%
Acute Migraine
25%
Medication Treatment
25%
Physical Impairment
25%
Everyday Activities
25%
Points Reduction
25%
Treatment Difference
25%
Domain Scores
12%
Adverse Events
12%
Migraine Frequency
12%
Phase II Study
12%
Injection Pain
12%
Trial Registration
12%
Activity Domains
12%
Upper Respiratory Tract Infection
12%
Safety Events
12%
Physical Impacts
12%
Amgen
12%
Preventive Treatment
12%
Calcitonin Receptor
12%
Reduction Rate
12%
Change from Baseline
12%
Efficacy Analysis
12%
Medication Use
12%
Least Mean Square
12%
Calcitonin Gene-related Peptide
12%
Monoclonal Antibody
12%
Adverse Events Profile
12%
Placebo-controlled
12%
Nasopharyngitis
12%
Randomized Double-blind
12%
Migraine Pathophysiology
12%
Pharmacology, Toxicology and Pharmaceutical Science
Erenumab
100%
Migraine
100%
Episodic Migraine
100%
Placebo
46%
Adverse Event
15%
Physical Disease
15%
Pathophysiology
7%
Rhinopharyngitis
7%
Calcitonin Gene Related Peptide
7%
Human Monoclonal Antibody
7%
Upper Respiratory Tract Infection
7%
Injection Site Pain
7%
Calcitonin Gene Related Peptide Receptor
7%
Medicine and Dentistry
Migraine
100%
Erenumab
100%
Placebo
46%
Physical Disease
15%
Adverse Event
15%
Calcitonin Gene Related Peptide Receptor
7%
Prophylaxis
7%
Pathophysiology
7%
Calcitonin Gene Related Peptide
7%
Human Monoclonal Antibody
7%
Upper Respiratory Tract Infection
7%
Least Square Analysis
7%
Neuroscience
Erenumab
100%
Migraine
100%
Placebo
37%
Human Monoclonal Antibody
6%
Calcitonin Gene-Related Peptide Receptor
6%
Upper Respiratory Tract
6%
Calcitonin
6%